Celina G. Kleer

Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability.

WISP3 is a novel tumor suppressor gene of inflammatory breast cancer.

Genetic Changes in Chromosomes 1p and 17p in Thyroid Cancer Progression.

Detection of Epstein-Barr virus in rapidly growing fibroadenomas of the breast in immunosuppressed hosts.

Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions.

Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.

Lymphocytic mastitis and diabetic mastopathy: a molecular, immunophenotypic, and clinicopathologic evaluation of 11 cases.

Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells.

Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma.

Sentinel node biopsy prior to neoadjuvant chemotherapy.

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.

E-cadherin expression in primary carcinomas of the breast and its distant metastases.

WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer.

Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines.

WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer.

p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma.

Small (< 2.0-cm) breast cancers: mammographic and US findings at US-guided cryoablation--initial experience.

WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer.

A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.

Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis.

Alpha-methylacyl-CoA racemase protein expression is associated with the degree of differentiation in breast cancer using quantitative image analysis.

Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy.

Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.

Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy.

RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.

Is lobular carcinoma in situ as a component of breast carcinoma a risk factor for local failure after breast-conserving therapy? Results of a matched pair analysis.

The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.

Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.

A putative role for psoriasin in breast tumor progression.

Interobserver reproducibility in the diagnosis of flat epithelial atypia of the breast.

Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells.

Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues.

ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.

The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.

RhoC GTPase expression as a potential marker of lymph node metastasis in squamous cell carcinomas of the head and neck.

Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board.

Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast.

Significance of flat epithelial atypia on mammotome core needle biopsy: Should it be excised?

Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.

CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer.

Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: implications for tumor suppression.

Expression of polycomb group protein EZH2 in nevi and melanoma.

Sentinel lymph node biopsy for breast cancer: how many nodes are enough?

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients.

BRCA1 regulates human mammary stem/progenitor cell fate.

Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.

ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast.

Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression.

Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.

Tubular carcinoma and grade 1 (well-differentiated) invasive ductal carcinoma: comparison of flat epithelial atypia and other intra-epithelial lesions.

Residual disease after re-excision lumpectomy for close margins.

Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients.

An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.

Towards a new "stromal-based" classification system for human breast cancer prognosis and therapy.

AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.

Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia.

Carcinoma of the breast with medullary-like features: diagnostic challenges and relationship with BRCA1 and EZH2 functions.

Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary gland.

Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells.

Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.

African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study.

Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks.

Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer.

EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development.

Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.

CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer.

Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.

Survival of inflammatory breast cancer patients compared to non-inflammatory breast cancer patients in Egypt.

On how CCN6 suppresses breast cancer growth and invasion.

p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior.

Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition.

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer.

Discoidin domain receptor tyrosine kinases: new players in cancer progression.

Invasive breast carcinomas in Ghana: high frequency of high grade, basal-like histology and high EZH2 expression.

CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer.

Metaplastic carcinomas of the breast: diagnostic challenges and new translational insights.

RhoC impacts the metastatic potential and abundance of breast cancer stem cells.

Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women.

Inflammatory breast cancer in north Africa: comparison of clinical and molecular epidemiologic characteristics of patients from Egypt, Tunisia, and Morocco.

Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.

CCN6 knockdown disrupts acinar organization of breast cells in three-dimensional cultures through up-regulation of type III TGF-β receptor.

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast.

EZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasis.

Tissue-based identification of stem cells and epithelial-to-mesenchymal transition in breast cancer.

EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer.

Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity.

EZH2 expands breast stem cells through activation of NOTCH1 signaling.